Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies.
about
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?Redirecting T cells to hematological malignancies with bispecific antibodies.Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms.Immunotherapy with the trifunctional anti-CD20 × anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease.New developments in immunotherapy for lymphoma
P2860
Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Immunotherapy with the trifunc ...... -positive B cell malignancies.
@en
Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05
@nl
type
label
Immunotherapy with the trifunc ...... -positive B cell malignancies.
@en
Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05
@nl
prefLabel
Immunotherapy with the trifunc ...... -positive B cell malignancies.
@en
Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05
@nl
P2093
P2860
P356
P1476
Immunotherapy with the trifunc ...... -positive B cell malignancies.
@en
P2093
Arndt Borkhardt
Beate Winkler
Friedhelm R Schuster
Horst Lindhofer
Jürgen Hess
Michael Stanglmaier
Paul G Schlegel
Raymund Buhmann
Roland Meisel
Wilhelm Woessmann
P2860
P304
P356
10.1111/BJH.13242
P407
P577
2014-12-11T00:00:00Z